Research to know,
know to prevent and cure

The Impact of Bone Metastasis Location in the Clinical Outcome of Patients with Metastatic Renal Cell Carcinoma (mRCC): An Analysis from the Latin American Renal Cancer Group (LARCG)

Downlodad

Background:

Tumor burden and metastatic disease sites are well-established prognostic factors in many malignancies, including metastatic Renal Cell Carcinoma (mRCC)

Objective:

We aimed to evaluate the impact of bone metastasis (BM) location on clinical outcome of mRCC patients.

Figure 1: Overall Survival for the entire patient cohort.

Figure 2: Overall Survival: a Comparison Between Groups with Spinal Bone Metastasis and Non-spinal Bone Metastasis.

Last news

Last video

Posición de los trocares para cirugía laparoscópica y robótica de riñón y pélvica de acuerdo a la anatomía

View all videos

Week Article

  • January 11, 2021

    Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis

    Background: Although grading systems have been proposed for chromophobe renal cell carcinoma (ChRCC), including a three-tiered system by Paner et al (Paner GP, Amin MB, Alvarado-Cabrero I, et al. A novel tumor gradingscheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol 2010;34:1233–40), none have gained clinical acceptance, and the World Health Organization (WHO) currently recommends against grading ChRCC. ...

View all articles

About us

The LARCG (Latin American Renal Cancer Group) is a group of scientific and educational, multicentric, multidisciplinary and independent. It is not for profit, and the term of operation is indeterminate. It consists of Urologists, Pathologists and Oncologists, as well as professionals and researchers related to the field of health, belonging to Hospitals in Latin America, Spain and the United States.

Read more

Last Tweets

LARCGFollow

LARCG
larcg_orgLARCG@larcg_org·
4 Dec

I am proud that the LARCG presents information on kidney cancer from Latin America. I appreciate the commitment and conviction of each member. @StenioZequi, @nolazcomd, @DrAndreFay, @montypal

2
Reply on Twitter 1335001681206063105Retweet on Twitter 13350016812060631052Like on Twitter 13350016812060631055Twitter 1335001681206063105
Retweet on TwitterLARCG Retweeted
TiansterZhangTian Zhang, MD, MHS@TiansterZhang·
7 Nov

@kaelin_lab @DanaFarberNews gives highlight keynote address #IKCS2020. His seminal @NobelPrize winning work elucidating biology & mechanisms of VHL-loss & HIF2a oncogenic activity drives VEGFR & HIF2a inhibitor development, fundamental treatment for #kidneycancer today.

4
Reply on Twitter 1325101676592852993Retweet on Twitter 13251016765928529936Like on Twitter 132510167659285299317Twitter 1325101676592852993
Load More...

Sponsor

Associates

You don't have permission to register